Navigation Links
Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
Date:3/27/2014

JUPITER, FL March 27, 2014 The outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key Westbefore that, the disease hadn't struck Florida in more than 70 years.

Now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.3 million to study a category of viruses that cause dengue fever, West Nile, yellow fever and other diseases spread by mosquitoes and ticks. These diseases can result in flulike symptoms, extreme pain (dengue has been called "bone-break fever") and, in some cases, encephalitis.

This family of viruses, called "flavivirus," affect some 2.5 billion people worldwide and cause hundreds of thousands of deaths each year. There are no antiviral treatments and a just handful of vaccines that provide protection against only a few of these diseases.

The principal investigator for the new five-year study is TSRI Associate Professor Hyeryun Choe, who will lead the effort to understand the virus's mode of infection and how new therapies might interrupt it.

"Flavivirus uses a very clever method of infection," Choe said. "It's like using a side door to enter a house when the front door is locked."

The viruses take advantage of the process that normally occurs during programmed cell death. During programmed cell death ("apoptosis"), a lipid usually found on the inner side of the cell membranes, specifically phosphatidylserine (PS), shifts to the surface, making itself readily available to any passing cellular stranger. This is where the trouble begins.

When cells are dying from a flavivirus infection, their freshly exposed PS is grabbed by the exiting virus, and phagocytescells that devour invading pathogens and dead and dying cellsengulf the virus as if it were a dying cell. Once engulfed by the phagocyte, the virus quickly turns the cell's own biology on its head, forcing it to produce copies of the virus.

While some viruses (influenza A for example) do not use PS in their life cycle, the flavivirus exploits this opportunity to the hilt. Infection of cells by dengue or West Nile viruses is markedly enhanced when phagocytes express receptors that recognize and bind PS.

It appears, however, that flaviviruses use only a subset of these receptors. The high selectivity, and the potency with which some of these receptors promote flavivirus infection, suggest only a small number of receptors might be effectively targeted to treat these diseases.

"We want to understand which PS receptors contribute the most to flavivirus infections and how we might block them," Choe said. "Our studies are designed to offer insights useful in the development of new therapies."


'/>"/>
Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps researchers recommend mobile compression device to prevent DVT after joint surgery
2. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
3. Scripps Health Launches Pilot Study of Wireless Vital Signs Device
4. OKeeffe Foundation donates $250,000 to fund Scripps Florida neuroscience training program
5. Scripps Research study underlines potential of new technology to diagnose disease
6. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
7. Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
8. Scripps Florida scientists develop new compound that reverses fatty liver disease
9. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
10. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
11. Scripps Research Institute study points to potential new therapies for cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the greater Fort Collins area, has unveiled a collaboration with nonprofit ... involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System ... AMN Healthcare: Susan Salka , 43rd President of the United States of America: ... My Life In and Out of the Ring: Sugar Ray Leonard , JD, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... Health on VoiceAmerica, recently talked on her program about how she is looking forward ... remind listeners of an important distinction. World Water Day, Kleyne pointed out, is an ...
(Date:3/23/2017)... Raton, FL (PRWEB) , ... March 23, 2017 ... ... of dietary supplements that help improve all aspects of people’s health and nutrition, ... website for nutritional products. , Natural Subsistence develops nutritional supplements that help ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)...  The U.S. Food and Drug Administration today granted ... adults and pediatric patients 12 years and older with ... not received prior chemotherapy. This is the first FDA-approved ... skin cancer. "While skin cancer is one ... form called Merkel cell cancer have not had an ...
(Date:3/23/2017)... AUSTIN, Texas , March 23, 2017 /PRNewswire/ ... www.digitalpharmacist.com ), a rapidly growing digital ... PocketRx, a mobile app that allows patients to ... including multi-store locations such as Denver Health Pharmacy, ... app. The acquisition helps Digital Pharmacist accelerate its ...
(Date:3/23/2017)... , March 23, 2017  Interpace Diagnostics Group, ... a fully integrated commercial company that provides clinically ... announced that it has entered into agreements to ... RedPath Shareholders ("RedPath") and concurrently terminate its royalty ... outstanding secured debt to RedPath amounting to $9.34 ...
Breaking Medicine Technology: